BIOMARIN PHARMACEUTICAL INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
BioMarin Pharmaceutical Inc. (BMRN) appointed Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to its Board of Directors. Plenge brings extensive experience in drug discovery and pharmaceutical industry leadership. BioMarin focuses on developing medicines for rare genetic conditions.
BIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size
BioMarin (BMRN) shares rose 5% after settling a global patent dispute with Ascendis (ASND) over Yuviwel, an achondroplasia drug. Ascendis will pay BioMarin royalties of 20% of US net sales and 18% internationally until 2030. The settlement resolves pending litigation, including a US ITC investigation. Both companies framed the outcome positively, highlighting long-term benefits and commercial flexibility.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning BMRN (BIOMARIN PHARMACEUTICAL INC). Coverage has skewed bullish: 4 bullish, 2 neutral, and 0 bearish.
Recent BMRN coverage spans financial news, corporate actions and mergers & acquisitions.
In the last 30 days, BMRN insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.2M). The most active reporter was Davis George Eric, EVP, Chief Legal Officer, with 1 filing.
The board appointment adds a seasoned research leader, potentially strengthening BioMarin's pipeline and investor confidence.
Board expansion and RSU grant are routine governance actions with limited immediate price impact.
Settlement provides a royalty stream and removes litigation risk.
Positive trial data could drive FDA approval expectations and boost BMRN stock.
The acquisition expands BioMarin's pipeline with the oral HPP candidate ALE1, while the licensing deal adds a royalty stream.
AlphAI scores every news story that mentions BMRN with an AI model for sentiment and relevance, and aggregates insider trades from BIOMARIN PHARMACEUTICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioMarin Pharmaceutical Inc. (BMRN) appointed Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to its Board of Directors. Plenge brings extensive experience in drug discovery and pharmaceutical industry leadership. BioMarin focuses on developing medicines for rare genetic conditions.
2 min readBIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size
1 min readBioMarin (BMRN) shares rose 5% after settling a global patent dispute with Ascendis (ASND) over Yuviwel, an achondroplasia drug. Ascendis will pay BioMarin royalties of 20% of US net sales and 18% internationally until 2030. The settlement resolves pending litigation, including a US ITC investigation. Both companies framed the outcome positively, highlighting long-term benefits and commercial flexibility.
2 min readBioMarin (BMRN) reported positive Phase 3 results for VOXZOGO in treating hypochondroplasia, showing significant improvements in growth metrics. The company submitted an sNDA to the FDA for this new indication, aiming for a 2027 launch. VOXZOGO is currently approved for achondroplasia.
2 min readBioMarin (BMRN) settled patents with Ascendis, gaining a non-exclusive global license and royalties for TransCon CNP. It also completed its acquisition of Alesta Therapeutics, now a subsidiary. Jefferies raised its price target for BMRN to $105.00.
1 min readBioMarin (BMRN) settled patent disputes with Ascendis (ASND) over achondroplasia treatments, agreeing to receive royalties on Yuviwel sales. Under the deal, BMRN will get 20% of U.S. sales and 18% in other regions until 2030. While this reduces competitive risk, Voxzogo's market share could still be pressured. Yuviwel generated €8M in Q2 2026, with further expansion planned. BMRN shares are up 13% YTD, trading at a P/S ratio of 3.06.
2 min readDavis George Eric (EVP, Chief Legal Officer) sold 17,557 shares of BIOMARIN PHARMACEUTICAL INC (BMRN) at $66.28 ($1.16M total) on 2026-09-02.
1 min readModerna's market value surged $45B after positive cancer vaccine data. Ultragenyx gained FDA approval for Genglycos, its first gene therapy. BioMarin acquired Alesta Therapeutics for $275M. AstraZeneca scrapped a Phase 3 lung cancer trial. Argenx reported positive Phase 3 data for Vyvgart. Capricor's CEO indicated FDA willingness to review updated cell therapy submission.
5 min readBioMarin and Ascendis Pharma settled a patent dispute, with Ascendis agreeing to pay BioMarin royalties. The dispute involved treatments for a genetic disorder. The agreement ends legal proceedings between the two companies.
1 min readBioMarin (BMRN) completed its acquisition of Alesta Therapeutics, adding ALE1, a clinical-stage drug for hypophosphatasia (HPP), to its portfolio. The deal makes Alesta a subsidiary, with BioMarin gaining control of ALE1's ongoing Phase 1/2a trial. Financial terms were not disclosed.
2 min read
